Literature DB >> 11206275

Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice.

M Suganuma1, Y Ohkura, S Okabe, H Fujiki.   

Abstract

Green tea is the most effective beverage for cancer prevention in humans. Looking at the concept of combination cancer chemoprevention, we previously reported the synergistic effects of (-)-epigallocatechin gallate (EGCG) with sulindac, and the additive effects of EGCG with tamoxifen, on cancer-preventive activity in human lung cancer cell line PC-9. This paper reports confirmation of the synergistic effects of EGCG with sulindac on the inhibition of intestinal tumors in multiple intestinal neoplasia (Min) mice. Treatment with both green tea extract and sulindac significantly reduced the number of tumors from 72.3 +/- 28.3 to 32.0 +/- 18.7 tumors per mouse, a decrease of 44.3%, whereas treatment with green tea extract alone or with sulindac alone reduced it to 56.7 +/- 3.5 and 49.0 +/- 12.7, respectively. The results also indicated that green tea extract inhibited tumor growth in Min mice almost as potently as sulindac itself did. The three treated groups did not show any adenocarcinomas, whereas 10.8% of the control group did. Since cancer-preventive agents like sulindac and tamoxifen are associated with adverse effects, we discuss the possibility of non-toxic, combination cancer chemoprevention with green tea, looking at the goal of truly effective cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206275     DOI: 10.1007/s004320000189

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  15 in total

Review 1.  EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment.

Authors:  Di Chen; Sheng Biao Wan; Huanjie Yang; Jian Yuan; Tak Hang Chan; Q Ping Dou
Journal:  Adv Clin Chem       Date:  2011       Impact factor: 5.394

Review 2.  Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds.

Authors:  Hirota Fujiki; Eisaburo Sueoka; Tatsuro Watanabe; Masami Suganuma
Journal:  J Cancer Res Clin Oncol       Date:  2014-12-28       Impact factor: 4.553

Review 3.  Tea and cancer prevention: molecular mechanisms and human relevance.

Authors:  Chung S Yang; Joshua D Lambert; Jihyeung Ju; Gang Lu; Shengmin Sang
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-29       Impact factor: 4.219

Review 4.  Challenging the effectiveness of green tea in primary and tertiary cancer prevention.

Authors:  Hirota Fujiki; Kazue Imai; Kei Nakachi; Masahito Shimizu; Hisataka Moriwaki; Masami Suganuma
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-15       Impact factor: 4.553

Review 5.  Chemoprevention of head and neck cancer with green tea polyphenols.

Authors:  Joseph W Kim; A R M Ruhul Amin; Dong M Shin
Journal:  Cancer Prev Res (Phila)       Date:  2010-07-27

Review 6.  Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system.

Authors:  Denis E Corpet; Fabrice Pierre
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-05       Impact factor: 4.254

Review 7.  Tea polyphenols for health promotion.

Authors:  Naghma Khan; Hasan Mukhtar
Journal:  Life Sci       Date:  2007-06-28       Impact factor: 5.037

Review 8.  Inhibition of carcinogenesis by tea constituents.

Authors:  Jihyeung Ju; Gang Lu; Joshua D Lambert; Chung S Yang
Journal:  Semin Cancer Biol       Date:  2007-07-04       Impact factor: 15.707

Review 9.  Prevention and treatment of cancers by immune modulating nutrients.

Authors:  Naveena B Janakiram; Altaf Mohammed; Venkateshwar Madka; Gaurav Kumar; Chinthalapally V Rao
Journal:  Mol Nutr Food Res       Date:  2016-03-09       Impact factor: 5.914

10.  Dietary antioxidants protect gut epithelial cells from oxidant-induced apoptosis.

Authors:  M J Miller; F M Angeles; B K Reuter; P Bobrowski; M Sandoval
Journal:  BMC Complement Altern Med       Date:  2001-12-10       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.